Vivo Capital, LLC Buys Insmed Inc, CymaBay Therapeutics Inc, uniQure NV, Sells Biohaven Pharmaceutical Holding Co, Apellis Pharmaceuticals Inc, Nabriva Therapeutics PLC

• New Purchases: INSM, QURE, DERM, MTNB, DTIL, SBBP,
• Added Positions: CBAY, KNSA, KDMN,
• Reduced Positions: BHVN, CRNX, ASND, APLS, NBRV, CDXS, TRVN, ZLAB, GNCA, SNSS,
• Sold Out: ARVN, FOMX,

For the details of Vivo Capital, LLC's stock buys and sells, go to https://www.gurufocus.com/guru/vivo+capital%2C+llc/current-portfolio/portfolio

1. Ascendis Pharma A/S (ASND) - 2,046,832 shares, 24.23% of the total portfolio. Shares reduced by 5.54%
2. Crinetics Pharmaceuticals Inc (CRNX) - 3,375,169 shares, 7.73% of the total portfolio. Shares reduced by 11%
3. Codexis Inc (CDXS) - 2,618,951 shares, 5.41% of the total portfolio. Shares reduced by 3.52%
4. Arrowhead Pharmaceuticals Inc (ARWR) - 2,328,475 shares, 4.30% of the total portfolio.
5. KalVista Pharmaceuticals Inc (KALV) - 1,359,149 shares, 3.91% of the total portfolio.

Vivo Capital, LLC initiated holding in Insmed Inc. The purchase prices were between $13.12 and $31.15, with an estimated average price of $25.71. The stock is now traded at around $27.68. The impact to a portfolio due to this purchase was 3.42%. The holding were 1,170,290 shares as of .

Vivo Capital, LLC initiated holding in uniQure NV. The purchase prices were between $27.39 and $68.41, with an estimated average price of $44.1. The stock is now traded at around $57.68. The impact to a portfolio due to this purchase was 1.08%. The holding were 180,336 shares as of .

Vivo Capital, LLC initiated holding in Dermira Inc. The purchase prices were between $6.19 and $14.13, with an estimated average price of $8.29. The stock is now traded at around $10.15. The impact to a portfolio due to this purchase was 0.95%. The holding were 700,000 shares as of .

Vivo Capital, LLC initiated holding in Matinas BioPharma Holdings Inc. The purchase prices were between $0.6 and $1.41, with an estimated average price of $1.07. The stock is now traded at around $0.90. The impact to a portfolio due to this purchase was 0.75%. The holding were 6,818,181 shares as of .

Vivo Capital, LLC initiated holding in Precision BioSciences Inc. The purchase prices were between $17.44 and $17.95, with an estimated average price of $17.7. The stock is now traded at around $13.15. The impact to a portfolio due to this purchase was 0.51%. The holding were 280,511 shares as of .

Vivo Capital, LLC initiated holding in Strongbridge Biopharma PLC. The purchase prices were between $4.42 and $5.59, with an estimated average price of $4.91. The stock is now traded at around $3.17. The impact to a portfolio due to this purchase was 0.46%. The holding were 914,062 shares as of .

Vivo Capital, LLC added to a holding in CymaBay Therapeutics Inc by 126.93%. The purchase prices were between $7.87 and $13.42, with an estimated average price of $10.56. The stock is now traded at around $12.36. The impact to a portfolio due to this purchase was 1.54%. The holding were 2,056,000 shares as of .

Vivo Capital, LLC added to a holding in Kiniksa Pharmaceuticals Ltd by 218.44%. The purchase prices were between $15.93 and $28.09, with an estimated average price of $19.5. The stock is now traded at around $15.41. The impact to a portfolio due to this purchase was 1.05%. The holding were 843,478 shares as of .

Vivo Capital, LLC added to a holding in Kadmon Holdings Inc by 20.58%. The purchase prices were between $2.08 and $2.99, with an estimated average price of $2.51. The stock is now traded at around $2.11. The impact to a portfolio due to this purchase was 0.57%. The holding were 12,606,605 shares as of .

Vivo Capital, LLC sold out a holding in Arvinas Inc. The sale prices were between $12.85 and $23.79, with an estimated average price of $17.74.

Vivo Capital, LLC sold out a holding in Foamix Pharmaceuticals Ltd. The sale prices were between $3.32 and $4.36, with an estimated average price of $3.74.